A new injection, RES-010, helps maintain weight loss in mice by transforming fat, while tirzepatide improves diabetes and BMI in teens.

A new weight loss injection, RES-010, shows promise in helping maintain long-term weight loss by reprogramming how the body processes fat and energy. It works by blocking a molecule called miR-22, boosting mitochondria activity, and converting energy-storing white fat into calorie-burning brown fat. Early studies in mice showed sustained weight loss without regaining weight after treatment stopped. Meanwhile, tirzepatide (Mounjaro) demonstrated significant benefits in children aged 10 to 17 with type 2 diabetes, improving blood sugar and reducing BMI. Both treatments offer potential for lasting metabolic improvements, though more research is needed to confirm long-term safety and effectiveness in humans.